Top News and Analysis for R&D and Executive Leaders

 

Week of 7.2.08

tbar.gif


Best Practices
Click here to
submit entries

Neil W Gibson of OSI Pharmaceuticals

Jeffrey Settleman Harvard Medical School and MGH Cancer Center

David Bailey of Chemoventures

N Claude Cohen of Synergix

-View All Webcasts

 

 

 
     

 

 

Top News

Scientists Identify Heparin Contaminant

March 19, 2008--Janet Woodcock, director of the US FDA’s Center for Drug Evaluation and Research, confirmed that the substance found in batches of Baxter International’s recalled heparin is over-sulfated chondroitin sulfate. Reuters

March 19, 2008--According to heparin experts, a chemically altered substance called over-sulfated chondroitin sulfate is probably the contaminant in the heparin distributed by Baxter International in the US. However, the researchers said they were not certain whether the contaminant is the cause of the allergic reactions linked to Baxter’s heparin, nor do they know precisely how or when the contaminant was mixed into the active ingredient. The New York Times (Free registration required)

Related:

The US FDA has received approval from the US State Department to establish eight full-time permanent FDA positions at US diplomatic posts in the People's Republic of China, pending authorization from the Chinese government. The permanent overseas offices in China will allow greater access for inspections and greater interactions with manufacturers to help assure that products that are shipped to the United States meet US standards for safety and manufacturing quality. FDA News Release (3/14)

According to the US FDA, all shipments of heparin—and active ingredients made to make it—will be stopped at the US border to test the products for signs of contamination. CNNMoney.com (3/14)


 

Genstruct: Patience, Persistence, and Payoff 
By John Russell

Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech.

Click here


 


PharmaWeek
is subject to the terms and conditions of use
Please read the important legal notices and disclaimers contained in these terms and
conditions of use.


Copyright 2005  Cambridge Healthtech Institute  |  250 First Avenue  |   Suite 300   |   Needham,  MA  02494
Phone: 781-972-5400  |   Fax: 781-972-5425